Schizophrenia News and Research

Latest Schizophrenia News and Research

ACADIA Pharmaceuticals proposes to sell common stock in underwritten public offering

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering.

4 Mar 2014

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.

4 Mar 2014

Elevated homocysteine not gender-specific in schizophrenia

Japanese researchers have demonstrated that both men and women with schizophrenia have significantly higher plasma homocysteine levels than healthy controls.

28 Feb 2014

BDNF abnormalities may predict bipolar disorder

Patients with bipolar disorder show abnormalities in the conversion of pro-brain derived neurotrophic factor to the mature form, which may be used to aid diagnosis of the condition.

28 Feb 2014

Protein that controls Drosophila nervous system may play role in reversing brain injuries in human

A protein that controls the metamorphosis of the common fruit fly could someday play a role in reversing brain injuries, said Duke University researchers.

28 Feb 2014

Further support for hippocampal volume as psychosis biomarker

Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes provide further evidence that reduced hippocampal volume is a consistent feature of schizophrenia.

27 Feb 2014

Attitudinal beliefs feed negative schizophrenia symptoms

Dysfunctional attitudes and low self-efficacy are associated with poorer functioning in patients with early schizophrenia, and this relationship is partly mediated by negative symptoms, shows research.

26 Feb 2014

Substance abuse worsens course of first-episode psychosis

Patients with first-episode psychosis who also present with substance abuse have a higher rate of hospitalisation after 12 months than their peers who do not, an Italian study reports.

25 Feb 2014

Understanding autism: an interview with Roberto Fernández Galán, PhD, Assistant Professor, Case Western Reserve School of Medicine

Autism does not come in just one flavour. It is a spectrum of disorders that share several features: impaired social interactions; impaired verbal and non-verbal communication; and restricted, repetitive behaviours.

25 Feb 2014

Study for understanding why people with autism have difficulties with social interaction

In a study to be published in Psychological Science, researchers from Aarhus University and the University of Copenhagen demonstrate that brain cells in what is called the mirror system help people make sense of the actions they see other people perform in everyday life.

25 Feb 2014

Researchers discover how brain cells change during learning and memories

A new University of British Columbia study identifies an important molecular change that occurs in the brain when we learn and remember.

25 Feb 2014

Regulators propose 1.9% cut to Medicare advantage payments

Federal regulators late Friday proposed cutting payments to private Medicare plans by 1.9 percent after recent lower health care spending growth. Insurers worry the cut could be much deeper than that after health law fees and other payment changes take effect, however, and say another cut could affect benefits for seniors.

25 Feb 2014

First Edition: February 24, 2014

Today's headlines include continuing coverage of Medicare Advantage payment rates, as well as a range of stories about the health law's Medicaid expansion and online insurance marketplaces.

24 Feb 2014

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Researchers have long known that people with autoimmune diseases, such as hepatitis, type 1 diabetes, multiple sclerosis and psoriasis, are at greater risk of developing schizophrenia.

24 Feb 2014

CUMC researchers find potential target for treating autism, schizophrenia, and other brain disorders

Columbia University Medical Center (CUMC) researchers have determined that a small region of the hippocampus known as CA2 is essential for social memory, the ability of an animal to recognize another of the same species.

24 Feb 2014

Factors predicting disengagement from psychosis early intervention identified

A study of first-episode psychosis patients in Hong Kong has found that those with fewer negative symptoms at presentation and poor medication compliance were more likely than others to disengage from an early intervention program.

21 Feb 2014

Epidemiological studies demonstrate that diseases of central nervous system protect against cancer

Epidemiological studies demonstrate that diseases of the central nervous system such as Alzheimer, Parkinson and schizophrenia protect against cancer. The most remarkable example is Alzheimer's disease, which can reduce the risk of suffering from cancer by up to 50%.

21 Feb 2014

Researchers identify gene variants that substantially increase risk for schizophrenia

Schizophrenia has long been known to be highly heritable and is present in approximately 1% of the population. Researchers have been following two paths in their pursuit of identifying schizophrenia risk genes.

20 Feb 2014

Stereotype awareness impacts self-esteem in schizophrenia

Patients with psychosis with higher self-esteem have less awareness of the stereotypes associated with mental health patients and their families, research shows.

19 Feb 2014

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.

19 Feb 2014

Schizophrenia News and Research

Latest Schizophrenia News and Research

ACADIA Pharmaceuticals proposes to sell common stock in underwritten public offering

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Elevated homocysteine not gender-specific in schizophrenia

BDNF abnormalities may predict bipolar disorder

Protein that controls Drosophila nervous system may play role in reversing brain injuries in human

Further support for hippocampal volume as psychosis biomarker

Attitudinal beliefs feed negative schizophrenia symptoms

Substance abuse worsens course of first-episode psychosis

Understanding autism: an interview with Roberto Fernández Galán, PhD, Assistant Professor, Case Western Reserve School of Medicine

Study for understanding why people with autism have difficulties with social interaction

Researchers discover how brain cells change during learning and memories

Regulators propose 1.9% cut to Medicare advantage payments

First Edition: February 24, 2014

People suffering from schizophrenia at greater risk of developing autoimmune diseases

CUMC researchers find potential target for treating autism, schizophrenia, and other brain disorders

Factors predicting disengagement from psychosis early intervention identified

Epidemiological studies demonstrate that diseases of central nervous system protect against cancer

Researchers identify gene variants that substantially increase risk for schizophrenia

Stereotype awareness impacts self-esteem in schizophrenia

Omeros doses first patient in second Phase 2 clinical trial of OMS824

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

How microRNA is transforming science: From discovery to diagnostics

Schizophrenia News and Research

Latest Schizophrenia News and Research

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in